Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Accumulated Expenses (2018 - 2025)

10x Genomics' Accumulated Expenses history spans 8 years, with the latest figure at $42.5 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 3.24% year-over-year to $42.5 million; the TTM value through Dec 2025 reached $42.5 million, up 3.24%, while the annual FY2025 figure was $42.5 million, 3.24% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $42.5 million at 10x Genomics, up from $35.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $56.6 million in Q4 2023 and bottomed at $16.8 million in Q1 2021.
  • The 5-year median for Accumulated Expenses is $32.2 million (2021), against an average of $33.4 million.
  • The largest annual shift saw Accumulated Expenses soared 158.6% in 2023 before it tumbled 48.24% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $31.6 million in 2021, then increased by 3.32% to $32.7 million in 2022, then skyrocketed by 73.37% to $56.6 million in 2023, then fell by 27.33% to $41.2 million in 2024, then rose by 3.24% to $42.5 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Accumulated Expenses are $42.5 million (Q4 2025), $35.8 million (Q3 2025), and $39.1 million (Q2 2025).